Apellis Medical Hub https://validator.w3.org/feed/docs/rss2.html Geographic Atrophy Risk Calculator Three PNH Opt In Form: PNH Collaborative Research Geographic Atrophy Risk Calculator Opt In Form: C3G & Primary-IC-MPGN C3G and Primary IC-MPGN Videos Geographic Atrophy April 1 2026 Pegcetacoplan for adolescents with C3G or IC-MPGN in phase 3 VALIANT (SWNC 2025 C3G) Geographic Atrophy Delayed Graft Function Medical Information Early Access & Compassionate Use Program Congress Presentations FSGS C3G / Primary IC -MPGN Science Retina Fellow Research Grant Patient Resources Geographic Atrophy Risk Calculator Two Geographic Atrophy v2 Pegcetacoplan Injection Mechanism of Action Video for GA Screening for referable macular pathologies in retirement centers using a nonmydriatic robotic OCT fundus camera (ARVO 2025 GA) Evaluating the thick double layer sign as a predictor for geographic atrophy progression in exudative eyes from the OAKS/DERBY trials (ARVO 2025 GA) Pegcetacoplan for adolescents with C3G or IC-MPGN in phase 3 VALIANT (NKF SCM 2025 C3G) Pegcetacoplan for posttransplant recurrent C3 glomerulopathy or primary (idiopathic) immune complex-mediated glomerulonephritis: The VALIANT trial (NKF SCM 2025 C3G) National Kidney Foundation Spring Clinical Meetings (NKF SCM) 2025 C3G Manuscripts Scientific Focus VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or posttransplant recurrent C3G or primary (idiopathic) IC-MPGN (SWNC 2025 C3G) Association for Research in Vision and Ophthalmology (ARVO) 2025 GA Topographic structure/function correlation between deep-learning quantified retinal pigment epithelium loss and ellipsoid zone thinning and retinal sensitivity (ARVO 2025 GA) American Nephrology Nurses Association (ANNA) National Symposium 2025 C3G C3 Glomerulopathy (C3G) and Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) VALIANT: Pegcetacoplan for C3G or primary (idiopathic) IC-MPGN (ANNA 2025 C3G) Geographic Atrophy GA The development of a time-to-event risk calculator to help assess risk of disease progression in cases of geographic atrophy (GA) secondary to AMD (ARVO 2025 GA) Southwest Nephrology Conference (SWNC) 2025 C3G Comparing EZ-based AI biomarkers to identify faster progressors in geographic atrophy by standard OCT (ARVO 2025 GA) Efficacy and safety of 12-week pegcetacoplan in kidney transplant recipients with recurrent C3G or primary IC-MPGN: 12-week results from the NOBLE study (Southwest Nephrology 2024 C3G) Southwest Nephrology 2024 C3G VALIANT: Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 3 Trial of Pegcetacoplan for Patients With Native or Posttransplant Recurrent C3G or Primary (Idiopathic) IC-MPGN (NKF SC Medical Symposium 2025 C3G) NKF Southern California Medical Symposium 2025 C3G VALIANT: Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 3 Trial of Pegcetacoplan for Patients With Native or Posttransplant Recurrent C3G or Idiopathic IC-MPGN (Mayo Clinic Nephrology 2025 C3G) Optimizing functional endpoints in geographic atrophy: Microperimetry insights from OAKS and GALE (ARVO 2025 GA) Mayo Clinic Nephrology, Hypertension and Kidney Transplantation Update for the Clinician 2025 C3G Efficacy of 12-week pegcetacoplan in kidney transplant recipients with recurrent C3 glomerulopathy (C3G) or immune complex membranoproliferative glomerulonephritis (IC-MPGN) (Mayo Clinic 2024 C3G) Analysis of AREDS oral micronutrient supplementation on geographic atrophy growth: Insights from the OAKS and DERBY studies (ARVO 2025 GA) Mayo Clinic Nephrology, Hypertension and Kidney Transplantation Update for the Clinician 2024 C3G Real-world survey on treatment pathways and patterns for patients with primary Immune Complex Membranoproliferative Glomerulonephritis (ISPOR EU 2024 C3G) Home